987 related articles for article (PubMed ID: 15269925)
21. Persistent use of against-label statin-fibrate combinations from 2003-2009 despite United States Food and Drug Administration dose restrictions.
Alford JC; Saseen JJ; Allen RR; Nair KV
Pharmacotherapy; 2012 Jul; 32(7):623-30. PubMed ID: 22570173
[TBL] [Abstract][Full Text] [Related]
22. Rosuvastatin-associated adverse effects and drug-drug interactions in the clinical setting of dyslipidemia.
Kostapanos MS; Milionis HJ; Elisaf MS
Am J Cardiovasc Drugs; 2010; 10(1):11-28. PubMed ID: 20104931
[TBL] [Abstract][Full Text] [Related]
23. The safety of niacin in the US Food and Drug Administration adverse event reporting database.
Alsheikh-Ali AA; Karas RH
Am J Cardiol; 2008 Apr; 101(8A):9B-13B. PubMed ID: 18375244
[TBL] [Abstract][Full Text] [Related]
24. Diplopia, blepharoptosis, and ophthalmoplegia and 3-hydroxy-3-methyl-glutaryl-CoA reductase inhibitor use.
Fraunfelder FW; Richards AB
Ophthalmology; 2008 Dec; 115(12):2282-5. PubMed ID: 18930555
[TBL] [Abstract][Full Text] [Related]
25. Does statin therapy initiation increase the risk for myopathy? An observational study of 32,225 diabetic and nondiabetic patients.
Nichols GA; Koro CE
Clin Ther; 2007 Aug; 29(8):1761-70. PubMed ID: 17919557
[TBL] [Abstract][Full Text] [Related]
26. Statin/fibrate combination in patients with metabolic syndrome or diabetes: evaluating the risks of pharmacokinetic drug interactions.
Davidson MH
Expert Opin Drug Saf; 2006 Jan; 5(1):145-56. PubMed ID: 16370963
[TBL] [Abstract][Full Text] [Related]
27. Fenofibric acid: in combination therapy in the treatment of mixed dyslipidemia.
Yang LP; Keating GM
Am J Cardiovasc Drugs; 2009; 9(6):401-9. PubMed ID: 19929038
[TBL] [Abstract][Full Text] [Related]
28. Statin-fibrate combination therapy.
Shek A; Ferrill MJ
Ann Pharmacother; 2001; 35(7-8):908-17. PubMed ID: 11485144
[TBL] [Abstract][Full Text] [Related]
29. Rhabdomyolysis and acute renal failure following a switchover of therapy between two fibric acid derivatives.
Kamaliah MD; Sanjay LD
Singapore Med J; 2001 Aug; 42(8):368-72. PubMed ID: 11764054
[TBL] [Abstract][Full Text] [Related]
30. Potential for conflict of interest in the evaluation of suspected adverse drug reactions: use of cerivastatin and risk of rhabdomyolysis.
Psaty BM; Furberg CD; Ray WA; Weiss NS
JAMA; 2004 Dec; 292(21):2622-31. PubMed ID: 15572720
[TBL] [Abstract][Full Text] [Related]
31. Statin safety: an appraisal from the adverse event reporting system.
Davidson MH; Clark JA; Glass LM; Kanumalla A
Am J Cardiol; 2006 Apr; 97(8A):32C-43C. PubMed ID: 16581327
[TBL] [Abstract][Full Text] [Related]
32. Muscle toxicity with statins.
Hedenmalm K; Alvan G; Ohagen P; Dahl ML
Pharmacoepidemiol Drug Saf; 2010 Mar; 19(3):223-31. PubMed ID: 20014178
[TBL] [Abstract][Full Text] [Related]
33. Pharmacologic options for aggressive low-density lipoprotein cholesterol lowering: benefits versus risks.
McKenney JM
Am J Cardiol; 2005 Aug; 96(4A):60E-66E. PubMed ID: 16098846
[TBL] [Abstract][Full Text] [Related]
34. Pharmacoepidemiology safety study of fibrate and statin concomitant therapy.
Enger C; Gately R; Ming EE; Niemcryk SJ; Williams L; McAfee AT
Am J Cardiol; 2010 Dec; 106(11):1594-601. PubMed ID: 21094360
[TBL] [Abstract][Full Text] [Related]
35. Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs.
Graham DJ; Staffa JA; Shatin D; Andrade SE; Schech SD; La Grenade L; Gurwitz JH; Chan KA; Goodman MJ; Platt R
JAMA; 2004 Dec; 292(21):2585-90. PubMed ID: 15572716
[TBL] [Abstract][Full Text] [Related]
36. Statin and statin-fibrate use was significantly associated with increased myositis risk in a managed care population.
McClure DL; Valuck RJ; Glanz M; Murphy JR; Hokanson JE
J Clin Epidemiol; 2007 Aug; 60(8):812-8. PubMed ID: 17606177
[TBL] [Abstract][Full Text] [Related]
37. Severe rhabdomyolysis associated with the cerivastin-gemfibrozil combination therapy: report of a case.
Lau TK; Leachman DR; Lufschanowski R
Tex Heart Inst J; 2001; 28(2):142-5. PubMed ID: 11453128
[TBL] [Abstract][Full Text] [Related]
38. High rates of adverse effects and patient unawareness of withdrawn lipid-lowering drug combination in a public hospital clinic.
Schiff GD; Keehr LM; Sai TT; Bult J
Pharmacoepidemiol Drug Saf; 2002 Dec; 11(8):643-5. PubMed ID: 12512238
[TBL] [Abstract][Full Text] [Related]
39. Statin safety and drug interactions: clinical implications.
Bottorff MB
Am J Cardiol; 2006 Apr; 97(8A):27C-31C. PubMed ID: 16581325
[TBL] [Abstract][Full Text] [Related]
40. Outcomes in 45 patients with statin-associated myopathy.
Hansen KE; Hildebrand JP; Ferguson EE; Stein JH
Arch Intern Med; 2005 Dec 12-26; 165(22):2671-6. PubMed ID: 16344427
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
